Washington is pouring real money into quantum, and the Q1 2026 reports from IonQ (NYSE:IONQ | IONQ Price Prediction) and IBM (NYSE:IBM) show why that matters. IonQ posted $64.67 million in revenue, up 755% year over year. IBM delivered $15.92 billion, up 9.46%. Same tailwind, two completely different financial realities. Hypergrowth on Borrowed Time vs. Cash Machine on Cruise Control IonQ’s quarter looks dazzling on the top line. CEO Niccolo de Masi called it “the biggest quarter in our company’s history” and raised full-year guidance to $260 million to $270 million. Wins include the first 256-qubit sale to the University of Cambridge, DARPA’s HARQ selection, a $39 million Space Development Agency HALO contract, and an MDA SHIELD slot. Underneath, the burn is real: an adjusted EBITDA loss of $96.75 million, operating cash flow of negative $151 million, and $128.52 million in stock-based comp diluting holders. IBM’s quarter looked nothing like that. Arvind Krishna highlighted “broad-based revenue growth across our segments”, with Software up 11.3%, Infrastructure up 15.3%, and IBM Z mainframe revenue surging 51%. Free cash flow landed at $2.22 billion, and the dividend was lifted to $1.69, the 31st consecutive annual hike. | Lens | IonQ | IBM | | Q1 Revenue | $64.7M | $15.92B | | Operating Cash Flow | -$151M | +$5.17B | | Funding Source | Equity offerings | Self-funded | One Begs Capital Markets. The Other Writes Its Own Checks. IonQ is racing to build a full-stack quantum supplier through the pending SkyWater deal and a pipeline of national network builds in Poland, Florida, and the U.S. Mid-Atlantic. That ambition is expensive. With $493.5 million in cash and a full-year EBITDA loss guided to $310 million to $330 million, IonQ remains structurally reliant on dilutive equity offerings. IBM’s quantum lab rides shotgun on a